Author

S. T. Staben

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Dey· 1 shared A. Fossoul· 1 shared A. Olivero· 1 shared B. L. Lee· 1 shared C. E. Stivala· 1 shared D. Demon· 1 shared D. Kirkpatrick· 1 shared D. Sampath· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Dey

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivMay 12, 2021

RTK-dependent inducible degradation of mutant PI3K alpha drives GDC-0077 (Inavolisib) efficacy

K. Song, K. Edgar, E. Hanan…·L. Friedman

The paper shows that GDC-0077 and taselisib degrade mutant PI3K alpha via HER2-dependent mechanisms, enhancing efficacy in PIK3CA-mutant breast cancer.

DOI 10.1158/2159-8290.cd-21-0072

humanproteomics

𝕏 PostBluesky

ImmunologybioRxivMay 11, 2019

MCC950/CRID3 potently targets the NACHT domain of wildtype NLRP3 but not disease-associated mutants for inflammasome inhibition

L. Vande Walle, I. B. Stowe, P. Sacha…·M. Lamkanfi

This study identifies the NACHT domain of wildtype NLRP3 as the target of MCC950/CRID3, showing it inhibits inflammasome activity but not CAPS-associated mutants.

DOI 10.1371/journal.pbio.3000354

mouseexperimental assay

𝕏 PostBluesky